Literature DB >> 17855545

Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope.

Tomoyuki Shiota1, Michio Okame, Sayaka Takanashi, Pattara Khamrin, Makiko Takagi, Kenji Satou, Yuichi Masuoka, Fumihiro Yagyu, Yuko Shimizu, Hideki Kohno, Masashi Mizuguchi, Shoko Okitsu, Hiroshi Ushijima.   

Abstract

Norovirus, which belongs to the family Caliciviridae, is one of the major causes of nonbacterial acute gastroenteritis in the world. The main human noroviruses are of genogroup I (GI) and genogroup II (GII), which were subdivided further into at least 15 and 18 genotypes (GI/1 to GI/15 and GII/1 to GII/18), respectively. The development of immunological diagnosis for norovirus had been hindered by the antigen specificity of the polyclonal antibody. Therefore, several laboratories have produced broadly reactive monoclonal antibodies, which recognize the linear GI and GII cross-reactive epitopes or the conformational GI-specific epitope. In this study, we characterized the novel monoclonal antibody 14-1 (MAb14-1) for further development of the rapid immunochromatography test. Our results demonstrated that MAb14-1 could recognize 15 recombinant virus-like particles (GI/1, 4, 8, and 11 and GII/1 to 7 and 12 to 15) and showed weak affinity to the virus-like particle of GI/3. This recognition range is the broadest of the existing monoclonal antibodies. The epitope for MAb14-1 was identified by fragment, sequence, structural, and mutational analyses. Both terminal antigenic regions (amino acid positions 418 to 426 and 526 to 534) on the C-terminal P1 domain formed the conformational epitope and were in the proximity of the insertion region (positions 427 to 525). These regions contained six amino acids responsible for antigenicity that were conserved among genogroup(s), genus, and Caliciviridae. This epitope mapping explained the broad reactivity and different titers among GI and GII. To our knowledge, we are the first group to identify the GI and GII cross-reactive monoclonal antibody, which recognizes the novel conformational epitope. From these data, MAb14-1 could be used further to develop immunochromatography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855545      PMCID: PMC2168978          DOI: 10.1128/JVI.00891-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  STAT1-dependent innate immunity to a Norwalk-like virus.

Authors:  Stephanie M Karst; Christiane E Wobus; Margarita Lay; John Davidson; Herbert W Virgin
Journal:  Science       Date:  2003-03-07       Impact factor: 47.728

2.  Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.

Authors:  Anne M Hutson; Robert L Atmar; Donald M Marcus; Mary K Estes
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Evaluation of a newly developed immunochromatographic method for detection of norovirus.

Authors:  Michio Okame; Hainen Yan; Shiho Akihara; Shoko Okitsu; Hideki Tani; Yoshiharu Matsuura; Hiroshi Ushijima
Journal:  Kansenshogaku Zasshi       Date:  2003-08

4.  SWISS-MODEL: An automated protein homology-modeling server.

Authors:  Torsten Schwede; Jürgen Kopp; Nicolas Guex; Manuel C Peitsch
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

5.  Mapping neutralizing and non-neutralizing epitopes on the capsid protein of feline calicivirus.

Authors:  K Geissler; K Schneider; U Truyen
Journal:  J Vet Med B Infect Dis Vet Public Health       Date:  2002-02

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP.

Authors:  Noritoshi Kitamoto; Tomoyuki Tanaka; Katsurou Natori; Naokazu Takeda; Shuji Nakata; Xi Jiang; Mary K Estes
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

9.  Precise characterization of norovirus (Norwalk-like virus)-specific monoclonal antibodies with broad reactivity.

Authors:  Tomoko Yoda; Yasuhiko Suzuki; Yoshitake Terano; Kenji Yamazaki; Naomi Sakon; Tsuyoshi Kuzuguchi; Hajime Oda; Teizo Tsukamoto
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

10.  Inter- and intragenus structural variations in caliciviruses and their functional implications.

Authors:  Rong Chen; John D Neill; Jacqueline S Noel; Anne M Hutson; Roger I Glass; Mary K Estes; B V Venkataram Prasad
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more
  25 in total

1.  Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens.

Authors:  Gabriel I Parra; Eugenio J Abente; Carlos Sandoval-Jaime; Stanislav V Sosnovtsev; Karin Bok; Kim Y Green
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Development of a latex agglutination test for norovirus detection.

Authors:  Heetae Lee; YoungBin Park; Misoon Kim; Youngmee Jee; Doo-Sung Cheon; Hae Sook Jeong; GwangPyo Ko
Journal:  J Microbiol       Date:  2010-08-20       Impact factor: 3.422

3.  Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle.

Authors:  Grant S Hansman; David W Taylor; Jason S McLellan; Thomas J Smith; Ivelin Georgiev; Jeremy R H Tame; Sam-Yong Park; Makoto Yamazaki; Fumio Gondaira; Motohiro Miki; Kazuhiko Katayama; Kazuyoshi Murata; Peter D Kwong
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies.

Authors:  Sue E Crawford; Nadim Ajami; Tracy Dewese Parker; Noritoshi Kitamoto; Katsuro Natori; Naokazu Takeda; Tomoyuki Tanaka; Baijun Kou; Robert L Atmar; Mary K Estes
Journal:  Clin Vaccine Immunol       Date:  2014-11-26

5.  Characterization of cross-reactive norovirus-specific monoclonal antibodies.

Authors:  Baijun Kou; Sue E Crawford; Nadim J Ajami; Rita Czakó; Frederick H Neill; Tomoyuki N Tanaka; Noritoshi Kitamoto; Timothy G Palzkill; Mary K Estes; Robert L Atmar
Journal:  Clin Vaccine Immunol       Date:  2014-11-26

Review 6.  Comprehensive review of human sapoviruses.

Authors:  Tomoichiro Oka; Qiuhong Wang; Kazuhiko Katayama; Linda J Saif
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

7.  Bioluminescent enzyme immunoassay for the detection of norovirus capsid antigen.

Authors:  Nozomi Sakamaki; Yoshiyuki Ohiro; Mitsuki Ito; Mitsuru Makinodan; Tsubasa Ohta; Wataru Suzuki; Susumu Takayasu; Harufumi Tsuge
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

8.  Antigenic and Cryo-Electron Microscopy Structure Analysis of a Chimeric Sapovirus Capsid.

Authors:  Naoyuki Miyazaki; David W Taylor; Grant S Hansman; Kazuyoshi Murata
Journal:  J Virol       Date:  2015-12-23       Impact factor: 5.103

9.  Nanobody binding to a conserved epitope promotes norovirus particle disassembly.

Authors:  Anna D Koromyslova; Grant S Hansman
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

10.  A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: a case study using monoclonal antibodies against the West Nile virus E protein.

Authors:  Galina F Denisova; Dimitri A Denisov; Jeffrey Yeung; Mark B Loeb; Michael S Diamond; Jonathan L Bramson
Journal:  Mol Immunol       Date:  2008-08-29       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.